Brief: Apimeds Welcomes FDA Draft Guidance As Catalyst For Advancing Apitox Non-Opioid Pain Program
12/09/2025 02:55
Sept 11 (Reuters) - Apimeds Pharmaceuticals US Inc APUS.A: APIMEDS WELCOMES FDA DRAFT GUIDANCE AS CATALYST FOR ADVANCING APITOX NON-OPIOID PAIN PROGRAM APIMEDS PHARMACEUTICALS US INC - FDA GUIDANCE MAY ACCELERATE APIMEDS' APITOX PROGRAM Source text: ID:nBwlysdma Further company coverage: APUS.A ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Apimeds Pharmaceuticals US
See all newsBrief: Apimeds Pharmaceuticals Us Inc Vin Menon Continues To Serve As The Company’S Chief Executive Officer
Brief: Apimeds Pharmaceuticals Appoints Youngjik Cho As Chairman Of Board
Brief: Apimeds Pharmaceuticals Us Inc. Announces Material Breach Of Merger Agreement By Inscobee Inc And Apimeds Inc
Brief: E.F. Hutton Advises On Strategic Merger Between Apimeds And Mindwave
Brief: Apimeds And Mindwave Announce Merger, Integrating Biotech Growth With AI